BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most common primary brain cancer. GBMs commonly acquire resistance to standard-of-care therapies. Among the novel means to sensitize GBM to DNA-damaging therapies, a promising strategy is to combine them with inhibitors of the DNA damage repair (DDR) machinery, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Xavier, Mary-Ann, Rezende, Fernando, Titze-de-Almeida, Ricardo, Cornelissen, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394995/
https://www.ncbi.nlm.nih.gov/pubmed/34439854
http://dx.doi.org/10.3390/biom11081188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394995/
https://www.ncbi.nlm.nih.gov/pubmed/34439854
http://dx.doi.org/10.3390/biom11081188

Ejemplares similares